References
- Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–183. doi: 10.1056/NEJMra040832
- Lavens A, Chao S, Buysschaert M, et al. Initiative pour la Promotion de la qualite et de l’Epidemiologie du Diabete sucre (IPQED) – Rapport resultats 2014 – Direction operationnelle Sante Publique et Surveillance. Bruxelles Institut Scientifique de Sante Publique; 2016, Belgium: INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE.
- Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254–260.
- Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 U/ml provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 U/ml. Diabetes Care. 2015;38:637–643.
- Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 U/ml versus glargine 100 U/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217–2225.
- www.ema.europa.eu/docs/en_GB/…/WC500047935.pdf, Accessed date 17 February 2015
- Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabetic Medicine. 2006;23(8):879–886.
- Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142–2148.
- Koehler G, Treiber G, Wutte A, et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab. 2014 Jan;16(1):57–62.
- Gradišer M, Berković MC, Bilić-Ćurčić I. Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: pilot study. Diabetes Res Clin Pract. 2017 Jul;129:144–147.
- Owens DR. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Curr Med Res Opin. 2017;33(10):1821–1831.
- Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) on behalf of the EDITION 3 study investigators. Diabetes Obes Metab. 2015;17(4):386–394.
- Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859–867.